Fluoroscopy-free Ablation in Congenital Heart Disease of Moderate or Great Complexity

Overview

Journal J Interv Card Electrophysiol

Publisher Springer

Date 2021 Oct 25

PMID 34694539

Authors

Arjun K Mahendran

Sara Bussey

Philip M Chang

Affiliations

Soon will be listed here.

Abstract

Background: Fluoroscopy-free (FF) ablation has been demonstrated to be safe and successful in patients with structurally normal hearts, but has not been systematically evaluated in patients with congenital heart disease (CHD) of moderate or great (M/G) complexity. This study aimed to evaluate and compare feasibility, safety, and outcomes of FF ablation in patients with or without M/G-CHD.

Methods: Consecutive patients undergoing electrophysiologic study and intended catheter ablation over a 24-month period were included. Subgroups were created based on presence and complexity of CHD-M/G-CHD or simple complexity/no CHD (S/N-CHD). Cases with total radiation dose of zero qualified as FF. Demographic and peri-procedural variables and outcome data were analyzed.

Results: A total of 89 procedures were included with 62 comprising the S/N-CHD group and 27 comprising the M/G-CHD group. Of the M/G-CHD patients, 13 had CHD of great complexity (including 6 single ventricle/Fontan and 2 atrial switch patients). Patients with M/G-CHD were older, had higher BMI, had higher incidence of ventricular dysfunction, and greater incidence of complex arrhythmias. Fluoroscopy-free ablation was achieved in 59% of M/G-CHD and 69% of S/N-CHD patients. Both groups had similar rates of acute procedural success, recurrence, and complications. Fluoroscopy was primarily used to visualize pre-existing transvenous leads and peripheral venous anomalies or to guide transbaffle/transseptal puncture.

Conclusions: A fluoroscopy-free ablation approach is feasible, safe, and successful even in patients with M/G-CHD with comparable outcomes to those with S/N-CHD.

References

Canpolat U, Faggioni M, Della Rocca D, Chen Q, Ayhan H, Vu A . State of Fluoroless Procedures in Cardiac Electrophysiology Practice. J Innov Card Rhythm Manag. 2020; 11(3):4018-4029. PMC: 7192123. DOI: 10.19102/icrm.2020.110305. View

Casella M, Dello Russo A, Pelargonio G, Greco M, Zingarini G, Piacenti M . Near zerO fluoroscopic exPosure during catheter ablAtion of supRavenTricular arrhYthmias: the NO-PARTY multicentre randomized trial. Europace. 2015; 18(10):1565-1572. PMC: 5072134. DOI: 10.1093/europace/euv344. View

Warnes C, Liberthson R, Danielson G, Dore A, Harris L, Hoffman J . Task force 1: the changing profile of congenital heart disease in adult life. J Am Coll Cardiol. 2001; 37(5):1170-5. DOI: 10.1016/s0735-1097(01)01272-4. View

Heidbuchel H, Wittkampf F, Vano E, Ernst S, Schilling R, Picano E . Practical ways to reduce radiation dose for patients and staff during device implantations and electrophysiological procedures. Europace. 2014; 16(7):946-64. DOI: 10.1093/europace/eut409. View

Walsh M, Noga M, Rutledge J . Cumulative radiation exposure in pediatric patients with congenital heart disease. Pediatr Cardiol. 2014; 36(2):289-94. DOI: 10.1007/s00246-014-0999-y. View

Andreassi M . Radiation risk from pediatric cardiac catheterization: friendly fire on children with congenital heart disease. Circulation. 2009; 120(19):1847-9. DOI: 10.1161/CIRCULATIONAHA.109.904458. View

Clay M, Campbell R, Strieper M, Frias P, Stevens M, Mahle W . Long-term risk of fatal malignancy following pediatric radiofrequency ablation. Am J Cardiol. 2008; 102(7):913-5. DOI: 10.1016/j.amjcard.2008.05.033. View

Bacher K, Bogaert E, Lapere R, De Wolf D, Thierens H . Patient-specific dose and radiation risk estimation in pediatric cardiac catheterization. Circulation. 2004; 111(1):83-9. DOI: 10.1161/01.CIR.0000151098.52656.3A. View

Smith G, Clark J . Elimination of fluoroscopy use in a pediatric electrophysiology laboratory utilizing three-dimensional mapping. Pacing Clin Electrophysiol. 2007; 30(4):510-8. DOI: 10.1111/j.1540-8159.2007.00701.x. View

10.

Percell R, Pike J, Olmsted R, Beideck J, Nunes H, Johnson K . The Grand SANS FLUORO (SAy No Series to FLUOROsopy) Study: Examining Fluoroscopy Use in More than 1,000 Ablation Procedures. J Innov Card Rhythm Manag. 2020; 11(9):4224-4232. PMC: 7510468. DOI: 10.19102/icrm.2020.1100903. View

11.

Bigelow A, Arnold B, Padrutt G, Clark J . Non-fluoroscopic cardiac ablation of neonates with CHD. Cardiol Young. 2016; 27(3):592-596. DOI: 10.1017/S1047951116001554. View

12.

Cano O, Sauri A, Plaza D, Osca J, Sancho-Tello M, Rueda J . Evaluation of a near-zero fluoroscopic approach for catheter ablation in patients with congenital heart disease. J Interv Card Electrophysiol. 2018; 56(3):259-269. DOI: 10.1007/s10840-018-0467-3. View

13.

Darrat Y, Morales G, Elayi C . The Effects of Catheter Ablation on Permanent Pacemakers and Implantable Cardiac Defibrillators. J Innov Card Rhythm Manag. 2020; 8(3):2630-2635. PMC: 7252655. DOI: 10.19102/icrm.2017.080303. View

14.

Clark B, Sumihara K, Berul C, Moak J . Off the pedal: Fluoroless transseptal puncture in pediatric supraventricular tachycardia ablation. Pacing Clin Electrophysiol. 2017; 40(11):1254-1259. DOI: 10.1111/pace.13195. View

15.

Mah D, Miyake C, Sherwin E, Walsh A, Anderson M, Western K . The use of an integrated electroanatomic mapping system and intracardiac echocardiography to reduce radiation exposure in children and young adults undergoing ablation of supraventricular tachycardia. Europace. 2013; 16(2):277-83. PMC: 4809978. DOI: 10.1093/europace/eut237. View

16.

Krause U, Backhoff D, Klehs S, Schneider H, Paul T . Transbaffle catheter ablation of atrial re-entrant tachycardia within the pulmonary venous atrium in adult patients with congenital heart disease. Europace. 2015; 18(7):1055-60. DOI: 10.1093/europace/euv295. View

17.

Combes N, Derval N, Hascoet S, Zhao A, Amet D, Le Bloa M . Ablation of supraventricular arrhythmias in adult congenital heart disease: A contemporary review. Arch Cardiovasc Dis. 2017; 110(5):334-345. DOI: 10.1016/j.acvd.2017.01.007. View